a écrit le 31 juillet 2015 à 13h35 Ebola vaccine:
"Interim analysis of the Guinea Phase III efficacy vaccine trial has shown VSV-EBOV has 100% efficacy in individuals but WHO said more conclusive evidence is needed to find its capacity to protect whole populations through herd immunity.
The Guinean national regulatory authority and ethics review committee has now approved the continuation of the trial. Results from the Guinea Phase III trial are published in The Lancet.
Sakoba Keita, Ebola response coordinator in Guinea, added: "This is Guinea's gift to West Africa and the world. The thousands of volunteers from Conakry and other areas of Lower Guinea, but also the many Guinean doctors, data managers and community mobilisers have contributed to finding a line of defence against a terrible disease."
"Interim analysis of the Guinea Phase III efficacy vaccine trial has shown VSV-EBOV has 100% efficacy in individuals but WHO said more conclusive evidence is needed to find its capacity to protect whole populations through herd immunity.
The Guinean national regulatory authority and ethics review committee has now approved the continuation of the trial. Results from the Guinea Phase III trial are published in The Lancet.
Sakoba Keita, Ebola response coordinator in Guinea, added: "This is Guinea's gift to West Africa and the world. The thousands of volunteers from Conakry and other areas of Lower Guinea, but also the many Guinean doctors, data managers and community mobilisers have contributed to finding a line of defence against a terrible disease."
